Recombinant mussel mucin with high DOPA content and preparation method thereof
Through Pichia cervical expression and tyrosinase activation technology, the DOPA content of recombinant mussel mucin is improved, and the problems of low efficiency and insufficiency of mussel mucin extraction in the prior art are solved, thus achieving efficient and environmentally friendly Recombinant mussel mucin preparation protects biodiversity.
Patent Information
- Application Number
- CN202411222626.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-02
- Publication Date
- 2024-12-06
AI Technical Summary
Existing mussel mucin products have low extraction efficiency, unfriendly environment and incomplete functions. The recombinant products have insufficient DOPA content and cannot completely replace natural mussel mucin.
Pichia cerevisiae cells were used to express recombinant mussel mucin and increase DOPA content by tyrosinase activation to prepare highly consistent recombinant mussel mucin, which contained treatment with pPICZA vector and specific activation solution.
The preparation of recombinant mussel mucin with high DOPA content has natural activity and high sequence homology, solves the problem of mussel slaughter, protects biodiversity, and meets the market's demand for DOPA content.
Smart Images

Figure CN119080903A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of biotechnology, in particular to a recombinant mussel mucin with high DOPA content and a preparation method thereof. Background Art
[0002] Mussels are a kind of crustacean marine organisms widely distributed in coastal and offshore areas. Their byssus glands can secrete byssus, and the byssus discs formed by the byssus can fix the mussels on the surface of various substrates. Studies have shown that this is related to the byssus secreted by mussels. The main component of its byssus is mussel foot protein (Mytilus edulis foot protein, Mfp), also known as mussel adhesive protein (MAP), which has high strength, high toughness and waterproofness. The coating formed by mussel adhesive protein is multifunctional and can achieve surface modification for multi-level materials. Mussel adhesive protein also has the characteristics of strong corrosion resistance, good biocompatibility, and no immune response. It has broad application prospects in the fields of marine engineering, biomedicine and surface chemistry.
[0003] There are two shortcomings of the existing technology:
[0004] First, existing mussel mucin products are mainly natural adhesive proteins extracted from mussel byssus glands, but since the secretion of mussel adhesive proteins is very low, about 30,000 mussels are needed to extract 1g of adhesive proteins; or genetic engineering is used to prepare recombinant mussel mucin, but this method has the disadvantages of being environmentally unfriendly, destroying biodiversity, destroying environmental homeostasis, low yield, low purification amount and complex purification process, which results in low efficiency and yield of preparing pure mussel mucin, greatly limiting the application of mussel mucin.
[0005] Second, most of the mainstream mussel mucin recombinant products on the market are non-tyrosinase activated products, which do not have natural activity. Or they have very poor homology with natural mussel mucin and cannot fully realize the functions of natural mussel mucin.
[0006] In view of this, the present invention is proposed. Summary of the invention
[0007] The first object of the present invention is to provide a recombinant mussel mucin to solve the above problems.
[0008] The second object of the present invention is to provide a nucleic acid molecule.
[0009] The third object of the present invention is to provide a carrier.
[0010] A fourth object of the present invention is to provide a cell.
[0011] The fifth object of the present invention is to provide a method for preparing recombinant mussel mucin with high DOPA content.
[0012] In order to achieve the above objectives, the following technical solutions are adopted:
[0013] In a first aspect, the present invention provides a recombinant mussel mucin, the amino acid sequence of the recombinant mussel mucin is shown in SEQ ID NO.1.
[0014] In a second aspect, the present invention provides a nucleic acid molecule encoding the recombinant mussel mucin.
[0015] As a further technical solution, the nucleotide sequence of the nucleic acid molecule is shown as SEQ ID NO.2.
[0016] In a third aspect, the present invention provides a vector, which carries the nucleic acid molecule.
[0017] As a further technical solution, the vector includes a pPICZA vector.
[0018] In a fourth aspect, the present invention provides a cell, wherein the cell carries the nucleic acid molecule, or contains the vector, or expresses the recombinant mussel mucin.
[0019] As a further technical solution, the cell comprises Pichia pastoris.
[0020] In a fifth aspect, the present invention provides a method for preparing a recombinant mussel mucin with a high DOPA content, comprising: using the cells to express the recombinant mussel mucin, and then preparing the recombinant mussel mucin after separation, purification and tyrosinase activation.
[0021] As a further technical solution, the activation is carried out by treating with an activation liquid;
[0022] The activation solution includes a buffer solution, wherein the buffer solution includes 20 mM sodium borate, 25 mM ascorbic acid, and tyrosinase;
[0023] The buffer comprises PBS buffer with a pH of 6-7.
[0024] As a further technical solution, the mass ratio of the tyrosinase to the recombinant mussel mucin is 1:(1600-2400);
[0025] The activation time is 1-3h.
[0026] Compared with the prior art, the present invention has the following beneficial effects:
[0027] The recombinant mussel mucin provided by the present invention has a high degree of consistency with the mussel mucin (mfp) in its natural form, with a sequence homology of more than 90%. After the recombinant mussel mucin is activated by tyrosinase, the DOPA content is more than 3% (the higher the DOPA content, the higher the value of the recombinant mussel mucin), and it has natural activity, which helps to solve the phenomenon of slaughtering mussels from the root and protect biodiversity. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0029] Figure 1 It is the SDS-PAGE electrophoresis picture;
[0030] Figure 2 This is the Western-blot identification result;
[0031] Figure 3 For the purification results;
[0032] Figure 4 The color development results of different proteins;
[0033] Figure 5 For the standard curve. DETAILED DESCRIPTION
[0034] The embodiments of the present invention will be described in detail below in conjunction with the embodiments and examples, but it will be appreciated by those skilled in the art that the following embodiments and examples are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. Based on the embodiments in the present invention, all other embodiments obtained by those of ordinary skill in the art without making creative work are within the scope of protection of the present invention. If specific conditions are not specified, proceed according to normal conditions or conditions recommended by the manufacturer. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be purchased commercially.
[0035] The term "vector" refers to a nucleic acid delivery vehicle into which nucleotides can be inserted. When a vector can express the protein encoded by the inserted nucleotides, the vector is called an expression vector. The vector can be introduced into a host cell by transformation, transduction or transfection, so that the genetic material elements it carries can be expressed in the host cell.
[0036] The vector is well known to those skilled in the art, including but not limited to: plasmid; phagemid; cosmid; artificial chromosome, such as yeast artificial chromosome (YAC), bacterial artificial chromosome (BAC) or P1-derived artificial chromosome (PAC); bacteriophage such as lambda phage or M13 phage and animal virus, etc. Animal viruses that can be used as vectors include but are not limited to retrovirus (including lentivirus), adenovirus, adeno-associated virus, herpes virus (such as herpes simplex virus), poxvirus, baculovirus, papillomavirus, papillomavirus. In some embodiments, the vector of the present invention contains regulatory elements commonly used in genetic engineering, such as enhancers, promoters, internal ribosome entry sites (IRES) and other expression control elements (such as transcription termination signals, or polyadenylation signals and poly-U sequences, etc.).
[0037] As used herein, the expressions "cell", "cell line" and "cell culture" are used interchangeably, and all such designations include progeny. Progeny may not necessarily be identical to the primary cell, e.g., differ in morphology and / or in genomic DNA, due to natural, accidental or deliberate mutation. "Transformants" and "transformed cells" include the primary subject cell and cultures derived therefrom.
[0038] In a first aspect, the present invention provides a recombinant mussel mucin, the amino acid sequence of the recombinant mussel mucin is shown in SEQ ID NO.1:
[0039] MKSLSIVVLVALVLIGSYAVQSDAGGNYYPKYKYPRGYKGGYNGYPRGNYGWNKGWKKGRWGRKYYGGGGSGGGGSMKLSTVVLVLVLVTLAATIDVGSGYDDYSDGYYPGSAYNYPFGSHWHGHGFKGKYYGKGKRYYYKFKRTGKYKYLKKARKYHRKGYKKHYGGSSS(SEQ ID NO.1).
[0040] The recombinant mussel mucin is highly consistent with the mussel mucin in its natural form, with a sequence homology of more than 90%. After being activated by tyrosinase, the recombinant mussel mucin has a DOPA content of more than 3%, which has natural activity and helps to solve the problem of mussel slaughter from the root and protect biodiversity.
[0041] In a second aspect, the present invention provides a nucleic acid molecule encoding the recombinant mussel mucin.
[0042] Nucleic acid molecules are the general term for deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), are biomacromolecules polymerized by many nucleotide monomers, and are one of the most basic substances of life. Nucleotide sequence refers to the order of arrangement of bases in DNA or RNA. Nucleic acid molecules contain cDNA, and in some cases, nucleic acid molecules can be modified for use in vectors of the present invention, such as for codon optimization. In some cases, for the purpose of cloning into a vector, the sequence can be designed to contain a terminal restriction site sequence. Nucleic acid molecules can be obtained from a variety of sources, such as by polymerase chain reaction (PCR) amplification of coding nucleic acids separated in one or more given cells or from the one or more given cells.
[0043] In a specific embodiment, the above nucleic acid molecules can be optimized according to the codon preference of the host cell and then artificially synthesized into gene fragments. It should be understood that nucleic acid molecules that can be translated into the above amino acid sequences are within the scope of protection of the present invention.
[0044] In some optional embodiments, the nucleotide sequence of the nucleic acid molecule is shown in SEQ ID NO.2:
[0045] ATGAAATCCCTGCTATTGTTGTTCTGGTGGCTCTGGTACTGATTGGCTCCTATGCAGTCCAGTCCGATGCGGGTGGCAACTATTACCCGAAATACAAGTATCCGCGTGGTTATAAAGGCGGTTACAAC GGTTACCCTCGCGGCAACTATGGTTGGAACAAAGGTTGGAAAAAAGGCCGTTGGGGTCGCAAATACTACGGTGGTGGTGGCTCTGGTGGCGGTGGTTCTATGAAACTGAGCACCGTGGTTCTGGTTCTG GTACTGGTCACCCTGGCCGCGACCATCGACGTGGGTTCTGGTTACGATGACTACAGCGACGGCTACTACCCAGGTAGCGCATACAACTACCCGTTCGGTTCTCACTGGCATGGTCACGGCTTCAAAGGC AAGTACTACGGCAAGGGCAAGCGTTATTACTACAAGTTCAAGCGTACTGGTAAATACAAATAACCTGAAGAAAGCTCGTAAGTACCACCGTAAAGGTTACAAAAAACACTACGGTGGCTCTAGCTCT(SEQ IDNO.2).
[0046] In a third aspect, the present invention provides a vector, which carries the nucleic acid molecule.
[0047] In some alternative embodiments, the vector comprises a pPICZA vector.
[0048] In a fourth aspect, the present invention provides a cell, wherein the cell carries the nucleic acid molecule, or contains the vector, or expresses the recombinant mussel mucin.
[0049] In some optional embodiments, the cells include but are not limited to Pichia pastoris, or other cells well known to those skilled in the art.
[0050] In a fifth aspect, the present invention provides a method for preparing a recombinant mussel mucin with a high DOPA content, comprising: using the cells to express the recombinant mussel mucin, and then preparing the recombinant mussel mucin after separation, purification and tyrosinase activation.
[0051] In some optional embodiments, the activation is treatment with an activation solution;
[0052] The activation solution includes a buffer solution, wherein the buffer solution includes 20 mM sodium borate, 25 mM ascorbic acid, and tyrosinase;
[0053] The buffer comprises PBS buffer with a pH of 6-7.
[0054] In some optional embodiments, the mass ratio of the tyrosinase to the recombinant mussel mucin can be, for example, but not limited to, 1:1600, 1:1800, 1:2000, 1:2200 or 1:2400;
[0055] The activation time may be, for example, but not limited to, 1 h, 2 h or 3 h.
[0056] The preparation method is simple and convenient. The DOPA content in the prepared recombinant mussel mucin is ≥3%, which can meet the current market demand for the DOPA content of the protein.
[0057] The present invention is further described below by means of specific examples. However, it should be understood that these examples are only used for more detailed description and should not be construed as limiting the present invention in any form.
[0058] Example 1
[0059] 1 Materials
[0060] 1.1 Plasmids and strains
[0061] The X33 engineered bacteria were maintained by Jinpu Noan Protein Engineering Technology (Beijing) Co., Ltd., and the mfp gene (nucleotide sequence as shown in SEQ ID NO.2, with a His tag added) was synthesized by Qingke Biotechnology Co., Ltd. and connected to the pPICZA vector.
[0062] 1.2 Reagents
[0063] Restriction endonucleases EcoR I and Not I were purchased from NEB (Beijing) Co., Ltd.; tryptone, yeast extract, bleomycin, and BCA protein quantification kit were purchased from Thermo Fisher; protein electrophoresis fluid, staining fluid, and decolorization fluid were purchased from GenScript Biotech Co., Ltd.; the remaining reagents were all domestically produced analytical grade.
[0064] 2 Methods
[0065] 2.1 Identification of recombinant plasmid pPICZA-mfp
[0066] The mfp gene was synthesized by Beijing Qingke Biotechnology Co., Ltd. and connected to the pPICZA vector, named pPICZA-mfp. The recombinant plasmid pPICZA-mfp was identified by double digestion with EcoR I and Not I, and the identified product was subjected to 1% agarose gel electrophoresis.
[0067] 2.2 Screening and identification of mfp expression strain pPICZA-mfp / X33
[0068] 2.2.1 Transformation of pPICZA-mfp positive plasmid
[0069] The pPICZA-mfp positive plasmid was transformed into X33 competent cells, coated on the surface of a YPDS solid culture medium plate containing bleomycin, and allowed to stand at 30°C for 20 minutes, inverted and cultured for 2 to 3 days, and the plate was transferred to a solid YPD plate containing bleomycin for high-copy transformant screening.
[0070] 2.2.2 Screening of pPICZA-mfp / X33 strain
[0071] Pick 10 single colonies from the plate and inoculate them in 10ml BMGY liquid medium. After culturing at 30℃280rpm overnight for about 24h, take a sample of the bacterial solution for microscopic examination to verify that there is no contamination by foreign bacteria. Transfer the bacterial solution to 10ml BMMY liquid medium, shake and culture at 30℃160rpm for 120h, take 200μl of the bacterial solution, centrifuge at 6000rpm for 5min, discard the supernatant, resuspend the bacterial solution with PBS, break the cells, centrifuge at 6000rpm for 5min, take 60μl of the supernatant, add 1 / 4 volume of 4×protein loading buffer, boil at 100℃ for 10min, and take a sample for SDS-PAGE electrophoresis.
[0072] A strain that was correctly identified by PCR and expressed efficiently was selected and named pPICZA-mfp / X33 strain.
[0073] 2.2.3 Western-blot identification of pPICZA-mfp / X33
[0074] The proteins separated in 2.2.2 were subjected to SDS-PAGE electrophoresis and wet-transferred to PVDF membranes; the membranes were blocked by incubation with TBST solution containing 5% skim milk at room temperature for 1 h; the membranes were washed with TBST for 5 min; HRP-Anti-His monoclonal antibody diluted with TBST was added and incubated at room temperature for 1.5 h; the membranes were washed with TBST for 3 times, 10 min each time; and the membranes were developed with TMD colorimetric reagent.
[0075] 2.3 Purification, activation and detection of mfp expression strain pPICZA-mfp / X33
[0076] 2.3.2 Purification
[0077] The pPICZA-mfp / X33 strain was lysed according to the ratio of lysis buffer 1:5, and then the supernatant was collected by centrifugation at 6000rpm for 5min, and the pH of the supernatant was adjusted to about 8.0, and then passed through the Ni column. The specific operation is as follows: first rinse the column with water for about 5 column volumes; after the column is rinsed with water, the column is balanced with Ni-A buffer (20mM PB 50mM NaCl, pH7.5) for about 5 column volumes. Load the sample, and the sample is the supernatant after the above cell lysis. After the loading is completed, the column is rinsed with Ni-Abuffer to wash away the sample and impurities that are not attached to the column, at least about 10 column volumes. Rinse the column with Ni-B buffer (20mM PB 50mM NaCl300mM imidazole, pH7.5) until the first protein peak drops, and collect the purified mfp protein in a sterile bottle.
[0078] 2.3.3 Activation
[0079] Self-produced tyrosinase was used for activation at a mass ratio of 1:2000, the activation time was 2h, and the activation system was as follows:
[0080]
[0081] In the prepared activation system, the concentration of sodium borate is 20 mM, and the concentration of ascorbic acid is 25 mM.
[0082] 2.3.4 Dialysis and freeze-drying
[0083] After activation, dialysis is performed, and then freeze-drying is performed to obtain a recombinant mussel mucin sample, and the pH of the sample is controlled to be about 4.5-8.5 after re-dissolution.
[0084] 3 Results
[0085] 3.1 Identification of recombinant plasmid pPICZA-mfp
[0086] 2 μl of the recombinant plasmid pPICZA-mfp was taken separately and double-digested with EcoR I and Not I. The digested products were subjected to 1% agarose gel electrophoresis, and two fragments of 3329 bp and 437 bp were respectively observed, indicating that the digestion was correct.
[0087] 3.2 Screening and identification of mfp expression strain pPICZA-mfp / X33
[0088] 3.2.1 Screening of pPICZA-mfp / X33
[0089] The colonies on the YPD plate were transferred to the YPD plate containing bleomycin and numbered. After inverting at 30°C for 16-18 hours, 10 single colonies were picked and cultured separately. After induction of expression, SDS-PAGE electrophoresis was performed. Compared with the negative control, an additional protein band at about 15-25 kDa was found, which was consistent with the expected mfp protein size. Figure 1 ( Figure 1 In the figure, the first column on the left is the marker, the second column is the negative control, and the third to twelfth columns are the experimental groups).
[0090] 3.2.2 Western-blot identification
[0091] After TMD color development, the supernatant lane induced a blue-green color band at about 15-25 kDa (see Figure 2 , Figure 2 In the figure, the first column on the left is the marker, the second column is the negative control, and the third to twelfth columns are the experimental groups). The results showed that the mfp expressed by the pPICZA-mfp / X33 strain can be specifically recognized by the Anti-His monoclonal antibody.
[0092] 3.3 Purification, activation and index detection of mfp expression strain pPICZA-mfp / X33
[0093] 3.3.1 Purification
[0094] The fermentation broth was collected and purified after 72 hours of induction. The final purification results were as follows: Figure 3 As shown in (SDS-PAGE electrophoresis results, the left column is marker, the right column is purified protein), the purified protein showed a band at 15-25 kDa.
[0095] The above bands were confirmed by WB (antibody: Anti-His) and were inferred to be the target protein.
[0096] 3.3.2 Activation
[0097] After activation, mfp containing DOPA is obtained, and the DOPA content is about ≥3%.
[0098] 3.3.3 Freeze-drying
[0099] After freeze-drying, the protein appears as white or light yellow solid powder.
[0100] 4 Conclusion
[0101] 4.1 The mfp gene was synthesized and connected to the pPICZA vector. The positive plasmid pPICZA-mfp identified by restriction digestion and sequencing was transformed into Pichia pastoris X33. A recombinant Pichia pastoris pPICZA-mfp / X33 strain expressing mfp was screened by PCR and SDS-PAGE. The supernatant of the strain was induced, and the results of Western-blot identification showed that mfp could be specifically recognized by Anti-His monoclonal antibody.
[0102] 4.2 The recombinant Pichia pastoris pPICZA-mfp / X33 strain was purified and cultured, and a total of 24 tubes were preserved, which were recorded as the F0 generation. A series of tests were conducted on the F0 generation yeast strains, and the results showed that when the yeast strains were streaked and inoculated into YPD solid medium containing bleomycin, the colonies were large and thick, with a smooth and moist surface, mostly milky white, and had a wine aroma, which was consistent with the characteristics of yeast culture; the yeast strains were observed to be round, oval or sausage-shaped under an ordinary optical microscope; and the PCR identification test showed a target fragment of 437 bp.
[0103] 4.3 At present, the protein content of the target protein is the highest after 72h of fermentation. The purification results can be recognized by Anti-His monoclonal antibody.
[0104] 4.4 After activation, the mfp containing DOPA is obtained, and the DOPA content is ≥3%, which can meet the current market demand for the DOPA content of this protein.
[0105] Example 2
[0106] 1. The color reaction shall be tested in accordance with Appendix 1 of YY / T1293.6-2020.
[0107] 1.1 Reagent preparation
[0108] 1.1.1 Glycine-potassium buffer (pH=10): Weigh 75 g of glycine and dissolve it in 400 mL of water. Adjust the pH to 10 with solid KOH, add water to make up to 500 mL, and store at 2°C to 8°C.
[0109] 1.1.2 Sodium borate solution: Weigh 2.5 g of sodium borate decahydrate and dissolve it in 40 mL of water. Heat ultrasonically at 40°C to dissolve.
[0110] 1.1.3 NBT staining solution: weigh 9 mg NBT and add 15 mL glycine-potassium buffer (A.1.1) to dissolve, mix well, and use immediately after preparation.
[0111] 2.1 Inspection steps
[0112] 2.1.1 Take 2 μL of sample and place it on a 0.2 μm nitrocellulose membrane (NC membrane) and mark the sample position.
[0113] 2.1.2 After the sample is absorbed by the NC membrane, place the NC membrane containing the sample in a 500 mL beaker, add 300 mL of pure water and ultrasonicate for 10 min.
[0114] 2.1.3 Take out the NC membrane and place it in a culture dish. Add NBT staining solution (A.1.3) and stain for 45 minutes in the dark.
[0115] 2.1.4 Take out the NC membrane and rinse it twice with sodium borate solution (A.1.2), then store it in the sodium borate solution overnight; then rinse it three times with pure water; observe whether blue-purple spots are generated at the sample mark, such as Figure 4 As shown (in the figure, the recombinant mussel mucin is the recombinant mussel mucin of the present invention, competitor A and competitor B are two types of mussel mucin purchased respectively, the extracted mussel mucin is extracted by the inventor from mussels, and the unactivated recombinant mussel mucin is the recombinant mussel mucin of the present invention that has not been activated).
[0116] Under alkaline conditions and with excess glycine as a reducing agent, the 1,2-benzenediol of the DOPA residue in the DOPA protein molecule can be oxidized and converted into a quinone compound. After adding oxidized nitro blue tetrazolium (NBT), insoluble blue-purple crystalline formazan is generated, and the higher the DOPA content, the more obvious the purple spots. Figure 4 It can be seen that the sample activated by the enzyme of the present invention presents purple spots and has a higher DOPA content than the extracted mussel mucin and the recombinant mussel mucin without activation treatment.
[0117] 3. The DOPA content determination shall be carried out in accordance with Appendix 2 of YY / T1293.6-2020.
[0118] 3.1 Reagent preparation
[0119] 3.1.1 Hydrochloric acid solution (0.012 mol / L): Take 0.2 mL of hydrochloric acid and dilute it to 200 mL with pure water.
[0120] 3.1.2 DOPA standard solution (200 μg / mL): Weigh 20 mg of DOPA standard and dilute to 100 mL with hydrochloric acid solution (C.1.1). Use immediately after preparation.
[0121] 3.1.3 Acidic reagent (0.516 mol / L): Take 4.3 mL of hydrochloric acid and dilute it to 100 mL with pure water.
[0122] 3.1.4 Alkaline reagent (1 mol / L): Weigh 4.0 g of sodium hydroxide (NaOH) and dilute to 100 mL with pure water.
[0123] 3.1.5 Nitrite reagent: Weigh 10 g of sodium molybdate dihydrate and 10 g of sodium nitrite, dissolve them in pure water and make up to 100 mL.
[0124] 3.2 Inspection steps
[0125] 3.2.1 Preparation of DOPA standard solution series: Take 0mL, 0.1mL, 0.5mL, 1.0mL, 1.5mL, 2.0mL, 2.5mL, and 3mL of DOPA standard solution (C.1.2) respectively, dilute to 10mL with hydrochloric acid solution (C.1.1), shake well, and set aside.
[0126] 3.2.2 Take 1 mL of the above series of standard solutions respectively, add 0.5 mL of acidic reagent (C.1.3) to each test tube, then add 1.5 mL of nitrous acid reagent (C.1.5) and 2 mL of alkaline reagent (C.1.4) to each test tube in turn (the alkaline reagent should be added within 5 minutes after the addition of the nitrous acid reagent), and shake well.
[0127] 3.2.3 Take 1 ml of the sample to be tested and place it in a 10 mL test tube and operate according to the above method. Use tube 0 as blank and use a 1 cm cuvette to measure the absorbance of the prepared standard solution and sample solution at a wavelength of 500 nm. If the absorbance of the solution to be tested exceeds the highest value of the standard curve, the sample needs to be diluted.
[0128] Note: If the sample interferes with the colorimetry, centrifuge it at 3000r / min for 10min and take the supernatant for colorimetry.
[0129] 3.2.4 Make a standard curve with DOPA concentration as the horizontal axis and absorbance as the vertical axis, such as Figure 5 (the horizontal axis is concentration, the unit is μg / mL, and the vertical axis is absorbance), and then the DOPA content of the sample is calculated based on the measured absorbance of the sample solution.
[0130] The DOPA content of the sample was measured according to the absorbance of the sample. It was calculated that the recombinant mussel mucin was 4.2%, the competitor A was 1.8%, the competitor B was 2.6%, the extracted mussel mucin was 0.7%, and there was no DOPA in the unactivated recombinant mussel mucin.
[0131] 4. Viscosity
[0132] The test was carried out according to the third method of viscosity determination method 0633 of Part IV of the 2020 edition of the Pharmacopoeia of the People's Republic of China.
[0133] After testing, the viscosity test results of several proteins were: recombinant mussel mucin 124.7mPa·s, competitor A 40.6mPa·s, competitor B 71.1mPa·s, extracted mussel mucin 29.5mPa·s, and unactivated recombinant mussel mucin 10.9mPa·s.
[0134] It should be noted that the implementation of the mussel mucin function is related to its viscosity. Generally, the higher the viscosity, the better its performance. Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention, rather than to limit it. Although the present invention is described in detail with reference to the above embodiments, a person skilled in the art should understand that the technical solutions described in the above embodiments can still be modified, or some or all of the technical features can be replaced by equivalents. However, these modifications or replacements do not make the essence of the corresponding technical solution deviate from the scope of the technical solution of each embodiment of the present invention.
Claims
1. A recombinant mussel mucin, characterized in that: The amino acid sequence of the recombinant mussel mucin is shown in SEQ ID NO.
1.
2. A nucleic acid molecule, characterized in that The nucleic acid molecule encodes the recombinant mussel mucin according to claim 1.
3. The nucleic acid molecule according to claim 2, characterized in that The nucleotide sequence of the nucleic acid molecule is shown in SEQ ID NO.
2.
4. A carrier, characterized in that The vector carries the nucleic acid molecule according to claim 2 or 3.
5. The carrier according to claim 4, characterized in that The vector includes a pPICZA vector.
6. A cell, characterized in that The cell carries the nucleic acid molecule according to claim 2 or 3, or contains the vector according to claim 4 or 5, or expresses the recombinant mussel mucin according to claim 1.
7. The cell according to claim 6, characterized in that The cell includes Pichia pastoris.
8. A method for preparing recombinant mussel mucin with high DOPA content, characterized in that: include: The recombinant mussel mucin is expressed by the cells according to claim 6 or 7, and then separated, purified and activated by tyrosinase to prepare the recombinant mussel mucin.
9. The preparation method according to claim 8, characterized in that: The activation is carried out by treating with an activation liquid; The activation solution includes a buffer solution, wherein the buffer solution includes 20 mM sodium borate, 25 mM ascorbic acid, and tyrosinase; The buffer comprises PBS buffer with a pH of 6-7.
10. The preparation method according to claim 8, characterized in that: The mass ratio of the tyrosinase to the recombinant mussel mucin is 1:(1600-2400); The activation time is 1-3h.
Citation Information
Patent Citations
Recombinant mussel mucoprotein with natural activity as well as preparation method and application thereof
CN117447611A
Method for producing high-yield recombinant type VI mussel mucin and application of high-yield recombinant type VI mussel mucin
CN118109499A
